The main objective of the present study was to establish whether the mixed s 1 /muscarinic ligand ANAVEX2-73, shown to be neuroprotective in Alzheimer's disease (AD) models in vivo and currently in clinical phase I/IIa, could have the ability to reduce the appearance of hyperphosphorylated Tau and amyloid-b 1-42 (Ab 1-42 ) in the Ab 25-35 mouse model of AD. We therefore first confirmed that Ab 25-35 injection induced hyperphosphorylation of Tau protein, by showing that it rapidly decreased Akt activity and activated glycogen synthase kinase-3b (GSK-3b) in the mouse hippocampus. Second, we showed that the kinase activation, and resulting Tau alteration, directly contributed to the amyloid toxicity, as co-administration of the selective GSK-3b inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole blocked both Tau phosphorylation and Ab 25-35 -induced memory impairments. Third, we analyzed the ANAVEX2-73 effect on Tau phosphorylation and activation of the related kinase pathways (Akt and GSK-3b). And fourth, we also addressed the impact of the drug on Ab 25-35 -induced Ab 1-42 seeding and observed that the compound significantly blocked the increase in Ab 1-42 and C99 levels in the hippocampus, suggesting that it may alleviate amyloid load in AD models. The comparison with PRE-084, a selective and reference s 1 receptor agonist, and xanomeline, a muscarinic ligand presenting similar profile as ANAVEX2-73 on M1 and M2 subtypes, confirmed that both muscarinic and s 1 targets are involved in the ANAVEX2-73 effects. The drug, acting synergistically on both targets, but with moderate affinity, presents a promising pharmacological profile.
INTRODUCTION
Alzheimer's disease (AD) is the most prevalent and devastating neurodegenerative dementia (Villard et al, 2011) . The two physiopathological hallmarks are extracellular deposition of amyloid-b (Ab) proteins, under the form of oligomers and plaques, and intracellular neurofibrillary tangles (NFTs). NFT are mainly constituted of hyper-and abnormally phosphorylated forms of the microtubule-associated Tau protein (Selkoe, 2004) . Although the role of both Ab and NFT in promoting neurotoxicity in the brain and related cognitive loss is highly recognized, the signalling pathways and underlying mechanisms are not yet clarified. It has been proposed that glycogen synthase kinase-3b (GSK-3b), a kinase with several roles in brain physiology, may be important as this is one of the major kinases responsible for Tau hyperphosphorylation (Kosik, 1992) and as it may be involved in Ab-mediated toxicity in AD. Overactivation of GSK-3b in neurons is associated with cognitive impairments, Ab production, neuronal death, and neuroinflammation (Bhat et al, 2004; Hooper et al, 2008) . GSK-3b overactivation results in Tau hyperphosphorylation, microtubule disruption, and neuronal apoptosis (Kosik, 1992; Bhat et al, 2000 , Hetman et al, 2000 Lucas et al, 2001; Beurel and Jope, 2006; DaRocha-Souto et al, 2012) . Inhibition of GSK-3b activity also directly participates in synaptic plasticity and memory consolidation by allowing, for instance, a blockade of long-term depression following the induction of long-term potentiation (Peineau et al, 2007) . Moreover, mice overexpressing GSK-3b showed impaired long-term potentiation and memory deficits (Hernandez et al, 2002) , which could be attributable to impaired integration of Akt and Wnt signalling onto mammalian target of rapamycin (mTOR) stimulation (Ma et al, 2010 (Ma et al, , 2011 . Ab peptides also activate directly GSK-3b in vitro and in vivo, although the mechanism remains unclear (Kim et al, 2003; Akiyama et al, 2005; Klementiev et al, 2007; Zussy et al, 2011) . Finally, GSK-3b could have a critical role in Ab production (for review, see Cai et al, 2012) . The kinase modulates APP processing and regulates Ab production by interfering with APP cleavage at the g-secretase complex level, as the APP and presenilin-1, a component of g-secretase complex, are substrates of GSK-3b. It may also enhance b-secretase activity and downregulate a-secretase through protein kinase C (PKC) and ADAMs, other substrates of the kinase. GSK-3b inhibitors have therefore been proposed as neuroprotective drugs in AD, in preclinical assays, and clinical trials (Bhat et al, 2004; Hu et al, 2009) .
In search of new therapeutic drugs with potent neuroprotective ability in AD and not directly targeting amyloid or Tau proteins, we identified agonists of the s 1 chaperone protein (Meunier et al, 2006) and more particularly mixed muscarinic/s 1 ligands belonging to the ANAVEX series (Vamvakides, 2002a, b) . The s 1 protein is a chaperone of the endoplasmic reticulum (ER), preferentially located on membranes forming focal contacts between ER and mitochondria (Hayashi and Su, 2007) . In basal conditions, the s 1 protein forms complex with other chaperones such as GRP78/BiP. Upon ER Ca 2 þ depletion or via ligand stimulation, the s 1 protein dissociates from BiP, leading to a prolonged Ca 2 þ signalling via inositol trisphosphate-1,4,5 receptors (Hayashi and Su, 2007) . Under subsequent chronic ER stress, the s 1 protein can also translocate to reach plasma membrane (Morin-Surun et al, 1999) , recruiting Ca 2 þ -dependent intracellular cascades, including phospholipase C (PLC) and PKC (Morin-Surun et al, 1999; Monnet et al, 2003) and modifying the composition and functionality of the lipid-rich microdomains known as lipid rafts Su, 2001, 2003) . Increasing or activating s 1 proteins in cells counteracts ER stress response, whereas decreasing or inactivating them enhances apoptosis (Hayashi and Su, 2007) . Modifying s 1 protein activation using effective agonists therefore mediates a unique pharmacological action on Ca 2 þ homeostasis and signal transduction pathways, with major impacts on cellular response and plasticity. The idea of developing mixed s 1 /muscarinic ligands was therefore based on the capability to simultaneously activate a neuroprotective pathway, eg, the M1/PLC/PKC pathway, and amplify it, through a concomitant activation of the s 1 protein (Vamvakides, 2002a, b; Espallergues et al, 2007; Villard et al, 2009 Villard et al, , 2011 . Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) presents such a mixed s 1 /muscarinic receptor profile, with a moderate affinity range. Indeed, the compound has a sub-micromolar affinity for the s 1 receptor (IC 50 ¼ 0.86 mM) and micromolar affinities for muscarinic human recombinant M1-M4 receptors (IC 50 ¼ 3.3-5.2 mM), sodium channel site 2 (IC 50 ¼ 5.1 mM), and N-methyl-D-aspartic acid receptors (IC 50 ¼ 8.0 mM; Vamvakides, 2002a, b) . The compound is a potent antiamnesic drug, in mice treated with the muscarinic receptor antagonist scopolamine, the N-methyl-D-aspartic acid receptor antagonist dizocilpine, or Ab 25-35 peptide (Villard et al, 2011) . The compound also showed, at sub-mg/kg intraperitoneal (i.p.) doses, a marked neuroprotective activity in vivo and prevented the oxidative stress, induction of caspases, cellular loss, and learning deficits observed 1 week after Ab 25-35 injection in mice (Villard et al, 2011) .
The toxicity induced after such central injection of the Ab 25-35 fragment in oligomeric form in mice and rats was repeatedly shown to result in neuroinflammation and reactive gliosis, pro-apoptotic caspases activity, oxidative stress, reduction in the number of neurons measured in hippocampal pyramidal cell layers, loss of cholinergic neurons, and memory deficits (Maurice et al, 1996; Delobette et al, 1997; Stepanichev et al, 2003 Stepanichev et al, , 2004 Stepanichev et al, , 2006 Meunier et al, 2006; Klementiev et al, 2007; Chavant et al, 2010; Villard et al, 2009 Villard et al, , 2011 Zussy et al, 2011) . It is at present widely used to detect the neuroprotective potential of new drugs and natural derivatives (Ruan et al, 2010; Kim et al, 2011; Lu et al, 2012; Wang et al, 2012; Yang et al, 2012) . Interestingly, the Ab 25-35 injection resulted not only in an aggressive amyloid toxicity but also in accumulation of endogenous Ab species and Tau hyperphosphorylation, as observed in AD physiopathology. One week after Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection, APP and Ab 1-42 levels were increased in the hippocampus and cortex, Ab-expressing cells could be visualized using immunohistochemistry and b-secretase cleavage products, such as the C-terminal fragment C99, could be detected (Klementiev et al, 2007; Chavant et al, 2010; Zussy et al, 2011) . Moreover, an increase in Tau phosphorylation on physiological or AD-related pathological epitopes induced by Ab 25-35 injection in mice was reported in several studies (Dudas et al, 2002; Klementiev et al, 2007; Deng et al, 2010) . The model indeed appeared highly suitable to analyze the time course of kinase activations (Akt and GSK-3b) within days after Ab injection and the resulting induction of Tau hyper-and abnormal phosphorylation.
Muscarinic ligands, and particularly M1 and M3 receptor agonists, have been shown to increase formation of sAPPa, preventing the formation of Ab, and to target GSK-3b (for reviews, see Fisher, 2008 Fisher, , 2012 . For instance, M1 receptor activation by AF267B resulted in elevation of PKC, extracellular signal-regulated protein kinase 1/2, ADAM17, and C83 fragment combined with decreased Ab 1-42 , C99, GSK-3b activity, and Tau hyperphosphorylation (Fisher, 2012) . AF267B also inhibited b-secretase (BACE1) expression in 3xTg-AD mice (Caccamo et al, 2006) . In the present study, we took advantage of the Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] model to analyze the ANAVEX2-73 effects on these parameters. However, as a prerequisite to the study, we first analyzed the activity of Akt and GSK-3b after Ab 25-35 injection and, by using the selective GSK-3b inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole (Tibpo), we showed that GSK-3b activation is a major component of the Ab 25-35 -induced Tau phosphorylation, toxicity, and behavioral deficits. Second, we examined the potency of ANAVEX2-73 to restore Akt and GSK-3b activities and prevent Tau hyperphosphorylation, on one hand, and to attenuate Ab 1-42 generation on the other hand. Moreover, the selective muscarinic ligand xanomeline and s 1 agonist PRE-084 were examined in parallel to define the muscucarinic and s 1 components in the observed effects of ANAVEX2-73.
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MATERIALS AND METHODS

Animals
Male Swiss OF-1 mice (Depré, St Doulchard, France) aged 7-9 weeks and weighing 32±2 g were used. They were housed in plastic cages in groups with free access to food and water, except during behavioral experiments. They were kept in a regulated environment (23±1 1C, 50-60% humidity) under a 12 h light/dark cycle (light on at 0800 hours). Behavioral experiments were carried out between 1000 and 1600 hours, in an experimental room within the animal facility. Mice were habituated 30 min before each experiment. All animal procedures were conducted in strict adherence to the EU Directive 86/609, modified by the decrees 87-848 and 2001-464.
Drugs and Administration Procedures
The amyloid-b [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide ) and scrambled Ab 25-35 peptide (Sc.Ab) were purchased from Genepep (Saint-Jean-de-Védas, France). They were solubilized in sterile distilled water at a concentration of 3 mg/ml and stored at À 20 1C until use. Before injection, peptides were incubated at 37 1C for 4 days, allowing Ab 25-35 , but not Sc.Ab, to form oligomers. They were administered intracerebroventricularly (i.c.v.) in a final volume of 3 ml per mouse, as previously described (Maurice et al, 1996 (Maurice et al, , 1998 Meunier et al, 2006; Villard et al, 2009) .
The GSK-3b inhibitor Tibpo was from Santa Cruz Biotechnology (GSK-3 Inhibitor II: sc-24020; Delaware, CA, USA; Naerum et al, 2002; Koh et al, 2005) . It was solubilized in dimethylsulfoxide 40% and injected i.c.v. simultaneously with the amyloid peptide (final dimethylsulfoxide concentration 10%). Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) was synthesized in the laboratory (Anavex Life Sciences). PRE-084 was a gift from Dr Tsung-Ping Su (Baltimore, MD, USA). Xanomeline was purchased from Sigma-Aldrich (St Quentin-Fallavier, France). Drugs were solubilized in physiological saline at the concentration of 5 mg/ml. They were then brought up to each dose by dilution and injected in a volume of 100 ml/20 g body weight. Animals were used between days 1 and 9 after i.c.v. injections for behavioral testing or killed before biochemical measures.
Spontaneous Alternation Performances
Each mouse, naive to the apparatus, was placed at the end of one arm in a Y-maze (three arms, 50 cm long, 601 separate) and allowed to move freely through the maze during a single 8-min session. The series of arm entries, including possible returns into the same arm, was recorded visually. An alternation was defined as entries into all three arms on consecutive trials. The number of the total possible alternations was therefore the total number of arm entries minus two and the percentage of alternation was calculated as (actual alternations/total possible alternations) Â 100.
Step-through Passive Avoidance Test
The apparatus consisted of an illuminated compartment with white polyvinylchloride walls (15 Â 20 Â 15 cm 3 high), a darkened compartment with black polyvinylchloride walls (15 Â 20 Â 15 cm 3 high), and a grid floor. A guillotine door separated each compartment. A 60-W lamp positioned 40 cm above the apparatus lit the white compartment during the experimental period. Scrambled foot shocks (0.3 mA for 3 s) were delivered to the grid floor using a shock generator scrambler (Lafayette Instruments, Lafayette, MA, USA). The guillotine door was initially closed during the training session. Each mouse was placed into the white compartment. After 5 s, the door was raised. When the mouse entered the darkened compartment and placed all its paws on the grid floor, the door was gently closed and the scrambled foot shock was delivered for 3 s. The step-through latency, ie, the latency spent to enter the dark compartment, and the number of vocalizations was recorded. The number of vocalizations did not differ among groups, indicating that shock sensitivity was unaffected by the treatments (data not shown). The retention test was carried out 24 h after training. Each mouse was placed again into the white compartment. After 5 s, the door was raised. The step-through latency was recorded up to 300 s. Animals entered in the dark compartment or were placed into it and the escape latency, ie, the time spent to return into the white compartment, was also measured up to 300 s. The two parameters were measured although they do not rely on similar memory stimuli. The step-through latency involves reinforced stimuli and is the direct measure of passive avoidance behavior. The escape latency relies on a supplementary sensory information, the contact with the grid floor that per se activates specific retrieval pathways, but includes an interfering information: the absence of electric shock in this compartment during the retention session.
Novel Object Recognition Memory
Six days after peptide and drug injections, mice were placed individually in a squared open field (50 Â 50 Â 50 cm 3 high) made in white Plexiglas with a floor equipped with infrared light-emitting diodes. On day 6 after peptide and drug injections, mice were habituated to the open field (session 1). During 10 min, the locomotor activity of the animals was captured through an IR-sensitive camera and analyzed using the Videotrack software (Viewpoint, Champagne-au-Mont-d'Or, France). The activity was analyzed in terms of total distance travelled (m), locomotor speed (cm/s), and percentage of presence in the 25 Â 25 cm 2 central area defined by the software. On day 7 after peptide and drug injections (session 2), two identical objects (50 ml plastic vials with caps) were placed at defined positions, at 1 4 and 3 4 of one diagonal of the open field. Each mouse was placed in the open field and the exploratory activity was recorded during 10 min. The activity was analyzed using the Nosetrack protocol (Viewpoint) in terms of number of contacts with objects and duration of the contacts. On day 8 after the injections (session 3), the object in position #2 was replaced by a novel one (a soft plastic chair feet protection) differing in color shape and texture from the familiar object. Each mouse was placed again in the open field and the exploratory activity recorded during 10 min. The activity was analyzed similarly. The preferential exploration index was calculated as the ratio of the number (or duration) of contacts with the object in position #2 over Blockade of Tau hyperphosphorylation and Ab 1-42 by ANAVEX2-73 V Lahmy et al the total number (or duration) of contacts with the two objects. As the analyses in terms of number of contacts or duration of contacts led to strictly similar results (data not shown), only the analyses in terms of number of contacts are presented. Animals showing no contact with one object or less than 10 contacts with objects, during the session 2 or 3, were discarded from the study. It represented 32 animals over 376, ie, 8.5%, attrition in this procedure.
Lipid Peroxydation Measures
Mice were killed by decapitation and brains were rapidly removed, the hippocampus dissected out, weighed, and kept in liquid nitrogen until assayed. After thawing, the hippocampus was homogenized in cold methanol (1/10w/v), centrifuged at 1000 g during 5 min and the supernatant collected. Homogenate was added to a solution containing 1 mM FeSO 4 , 0.25M H 2 SO 4 , 1 mM xylenol orange, and incubated for 30 min at room temperature. Absorbance was measured at 580 nm (A 580 1), and 10 ml of 1 mM cumene hydroperoxyde (CHP) was added to the sample and incubated for 30 min at room temperature, to determine the maximal oxidation level. Absorbance was measured at 580 nm (A 580 2). The level of lipid peroxydation was determined as CHP equivalents according to: CHP eq. ¼ A 580 1/A 580 2 Â [CHP (nmol)] Â dilution, and expressed as CHP eq. per wet tissue weight.
Murine Ab 1-40/42 Contents Measured by ELISA
Mice were killed by decapitation 7 days after Ab 25-35 injection and brains were rapidly removed, the hippocampus dissected out, weighted, frozen in liquid nitrogen, and stored at À 80 1C until assayed. After thawing, the hippocampus was homogenized in 50 mM Tris-150 mM NaCl buffer, pH 7.5, and sonicated for 20 s. After centrifugation (16 100 g for 15 min, 4 1C), supernatants were used for mouse Ab 1-40 ELISA assay (E90864Mu, Uscn Life Science, Euromedex, Souffelweyersheim, France) or for mouse Ab 1-42 ELISA assay (E90946Mu, Uscn Life Science), according to the manufacturer's instructions. Absorbance was read at 450 nm and sample concentration was calculated using the standard curve. Results were then expressed in pg of Ab 1-40/42 /mg of tissue.
Western Blotting
Mice were decapitated at indicated days after Ab 25-35 peptide injection. The hippocampus was removed on an ice-cold Petri dish and stored at À 80 1C. Tissues were homogenized by sonication in a lysis buffer (125 mM TrisHCl pH 6.8, 4% SDS, 20% glycerol) including a protease and phosphatase inhibitors cocktail (Roche Diagnostics, Meylan, France). Homogenates were heated at 70 1C for 10 min and centrifuged at 16 000 g for 30 min at 15 1C.
Protein concentration was determined using the Pierce BCA assay (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. Proteins, 20-50 mg per lane, were resolved on a 10% SDSpolyacrylamid gel, except for C99 determination where a 15% SDS-polyacrylamid gel was used. Proteins were then transferred to a PVDF membrane (GE Healthcare, Orsay, France). After 1 h blocking in 5% non-fat dry milk in a 20 mM Tris-buffered saline, pH ¼ 7.5, buffer containing 0.1% Tween-20 (TBS-T), membranes were incubated overnight at 4 1C with the primary antibodies (see Table 1 ). After brief washes, membranes were incubated for 1 h at room temperature with corresponding secondary antibody ( Table 1 ). The immunoreactive bands were visualized with the enhanced chemiluminescence reagent (ECL, Pierce Biotechnology) using a Lumi-Imager F1 Workstation (Roche Diagnostic). Then, membranes were stripped using the Restore Western Blot Stripping Buffer (Pierce Biotechnology) and incubated with anti-GSK-3b, anti-Tau, antiAkt, or anti-b-tubulin antibody (see Table 1 ). The intensity of peroxydase activity was quantified using the ImageJ software (NIH, Bethesda, MD, USA). 
Statistical Analyses
Alternation percentages and biochemical data were expressed as mean ± SEM. They were analyzed using one-way ANOVA (F values), followed by the Dunnett's post-hoc multiple comparison test. Passive avoidance latencies were expressed as median and inter-quartile range, as an upper cutoff time was set. They were analyzed using a Kruskal-Wallis non-parametric ANOVA (H values), followed by the Dunn's multiple comparisons test. Novel object contact preferences were analyzed using a one-sample t-test vs the no-preference level (50%). For reading clarity, ANOVA data were all reported in the figure legends. The level of statistical significance was po0.05.
RESULTS
Time Course for Akt and GSK-3b Kinase Activation after Ab 25-35 Injection in Mice
As schematized in Figure 1a , Tau hyperphosphorylation in the brain is mainly due to a decrease in Akt activity, which inactivates GSK-3b by phosphorylating the kinase on an inactivating epitope, Ser 9
. In parallel, an increase in the kinase phosphorylation on an activating site, Tyr 216 , putatively regulated by PYK2 activity, also contributes to GSK-3b activation and to the hyperphosphorylation of Tau (Figure 1a ). We therefore analyzed by western blot, the time course of Akt activation, by measuring the phospho (Ser 473 )Akt/total Akt ratio, and GSK-3b activation by )GSK-3b/total GSK-3b ratio. PI3K, phospho-inositide 3-kinase; PDK1/2, protein kinase B; PYK2, proline-rich tyrosine kinase 2; Akt, serine/threonine protein kinase; GSK-3b, glycogen synthase kinase-3b. Typical blots are shown above the graphs. Lanes were from the same blot but placed in the same treatment order as shown for the graph. Mice were administered i.c.v. with Sc.Ab or Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide (9 nmol) and killed 1, 3, 5, 7 days after injection. ANOVA: n ¼ 9-15 per group, F (4,60) ¼ 4.02, po0.01 in (b); n ¼ 7-12, F (4,42) ¼ 2.71, po0.05 in (c); n ¼ 6-8, F (4,37) ¼ 3.23, po0.05 in (d). *po0.05, **po0.01, ***po0.001 vs the Sc.Ab-treated group; Dunnett's test.
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The time-course analysis of Akt phosphorylation showed that significant decreases are observed at day 1 and 3 after Ab 25-35 injection as compared with Sc.Ab controls (Figure 1b) . The levels then progressively returned to control values. At day 7, a 15% decrease was still observable, but the comparison with Sc.Ab controls failed to reach significance. The time-course analysis of GSK-3b phosphorylation showed a significant decrease of the P(Ser 9 )GSK-3b/GSK-3b ratio only at day 7 after peptide injection. However, the phosphorylation on Tyr 216 rapidly and highly significantly increased at all times tested after the peptide injection. The protein loading and variation of the total kinase levels were checked using b-tubulin, and neither Akt nor GSK-3b expression was changed after Ab 25-35 injection (F (4,37) ¼ 1.24, p40.05 in Figure 1b and F (4,43) ¼ 0.51, p40.05 in Figure 1c) .
Although causal relationships remained hazardous from ex vivo measures, these observations indicated in a coherent manner that the Ab 25-35 injection provokes, within days after i.c.v. injection in mice, an inhibition of the phosphatidyl-inositol 3-kinase (PI3K)/Akt pathway leading to or reinforcing the activation of GSK-3b.
GSK-3b Activation is Involved in Ab 25-35 -induced Toxicity and Memory Impairments
In order to determine whether this Akt inactivation and GSK-3b activation could be deleterious, we treated animals with the GSK-3b inhibitor Tibpo, i.c.v. simultaneously with Ab 25-35 peptide. The level of oxidative stress in the hippocampus was analyzed 9 days after injections (Figure 2a ), in animals that were previously evaluated at the behavioral level on day 7 using spontaneous alternation in the Y-maze, a spatial working memory procedure (Figure 2b ) and on days 8 and 9 using passive avoidance, a long-term contextual procedure (Figure 2c and d) . A second batch of animals was tested at days 6-8 after injection in the novel object recognition procedure, a recognition memory highly impacted in AD (Figure 2e and f) .
Ab 25-35 provoked a þ 50% increase in lipid peroxydation levels that was prevented by Tibpo, with significant differences observed at the 0.3 and 1 nmol i.c.v. doses (Figure 2a) . The Tibpo treatment led to a dose-dependent, bell-shaped prevention of the appearance of Ab 25-35 -induced alternation deficits, with significant effects observed for the doses of 0.1 and 0.3 nmol (Figure 2b ). In the passive avoidance test, the Ab 25-35 -induced deficit in step-through latency and increase in escape latency were corrected by the drug, at the doses of 0.1, 0.3, and 1 nmol in a highly significant manner (Figure 2c and d) .
None of the treatment group affected the exploration of the two identical objects during the session 2 of the novel object recognition test, resulting in a 50% contacts for the object in position #2 (Figure 2e ). During session 3, Ab 25-35 -treated mice failed to preferentially explore the novel object, contrarily to Sc.Ab-treated mice (Figure 2f ). The Tibpo treatment dose-dependently prevented the recognition memory deficit, with highly significant differences at the doses of 0.3 and 1 nmol (Figure 2f ). The GSK-3b inhibitor was ineffective at the highest dose tested in Sc.Ab-treated mice on all responses. These data showed that GSK-3b activation is directly involved in the Ab 25-35 -induced toxicity and behavioral deficits in mice.
The GSK-3b Inhibitor Tibpo Blocked GSK-3b Activation and Tau Hyperphosphorylation in Ab 25-35 -injected Mice
At the active dose of 0.3 nmol i.c.v., we observed that Tibpo blocked the Ab 25-35 -induced increase in GSK-3b phosphorylation on Tyr 216 in the mouse hippocampus (Figure 3b) , with concomitantly no change in GSK-3b phosphorylation on Ser 9 (Figure 3a) . We analyzed the levels of hyperand abnormal phosphorylation of Tau protein induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in the hippocampus by using AT8 antibody, which recognizes, specifically P(Ser ) Tau, a pathological phosphorylation epitope. The Ab 25-35 treatment highly significantly increased AT8 immunoreactivity ( þ 236%, Figure 3c ) and AT100 labelling ( þ 82%, Figure 3d ). The Tibpo treatment significantly blocked both increases in AT8 and AT100 immunoreactivities (Figure 3c and d) .
We therefore confirmed that Ab 25-35 injection in mice results in Akt inactivation, GSK-3b activation, Tau phosphorylation, toxicity, and behavioral impairments and that this coherent scheme occurred in a GSK-3b-dependent manner.
ANAVEX2-73, and the Reference Ligands PRE-084 and Xanomeline, Blocked Ab 25-35 -induced Recognition Memory Deficits
The second part of the study consisted in the determination of the protective effect of ANAVEX2-73 on Tau phosphorylation and Ab 1-42 seeding, in comparison with two reference muscarinic and s 1 receptor agonists, namely xanomeline and PRE-084, respectively. The different drugs have been previously tested in several behavioral procedures, including spontaneous alternation and passive avoidance (Meunier et al, 2006; Villard et al, 2011) , but never using novel object recognition. We used this procedure to determine the most active doses of the three drugs to be selected in biochemical analyses. (Figure 4a ). However, during session 3, Ab 25-35 -treated mice failed to show a preferential exploration of the novel object, as compared with Sc.Ab-treated mice (Figure 4b ). The ANAVEX2-73 treatment dose-dependently blocked the recognition memory deficit, with a significant effect measured at 1 mg/kg (Figure 4b ). Animals treated with PRE-084 failed to show any difference in object exploration during session 2 (Figure 4c ), but also showed a significant reversion of the Ab 25-35 -induced deficits during session 3, at the dose of 1 mg/kg (Figure 4d) . Finally, the xanomeline treatment also showed no difference among groups in session 2 (Figure 4e ), but the drug alleviated the Ab 25-35 -induced deficits in session 3, with a significant effect at the lowest dose tested (Figure 4f ). These behavioral data confirmed that selective or mixed s 1 receptor agonists and M1 cholinergic receptor agonists are able to prevent the Ab 25-35 -induced learning impairment when they were injected at the same time as the peptide. These different treatment groups were then used for biochemical analysis of the hyperphosphorylation of Tau and Ab 1-40/42 generation.
The Drug Treatments Prevented Alterations in Kinase Activity and Tau Hyperphosphorylation
The impact of the drug treatments was first analyzed on Ab 25-35 -induced decrease in Akt phosphorylation on Ser 473 at 1 and 7 days after the peptide injection ( Figure 5 ). One day after injections, a significant 32-34% decrease in Akt phosphorylation was measured, which was significantly attenuated by ANAVEX2-73 at 0.1 and 1 mg/kg dose (Figure 5a ), PRE-084 at 1 mg/kg (Figure 5b) , and xanomeline at 0.5 mg/kg (Figure 5c ). Akt phosphorylation was still significantly decreased by 16-18% 7 days after injection. The ANAVEX2-73 treatment resulted only in a nonsignificant attenuation of the decrease in P(Ser 473 )Akt/Akt ratio at 0.1 and 0.3 mg/kg (Figure 5d ). At day 7, PRE-084 and xanomeline significantly blocked the decrease in P(Ser 473 )Akt/Akt ratio both at the dose of 1 mg/kg, each (Figure 5e and f, respectively).
Seven days after injections, ANAVEX2-73 attenuated the decrease in Ser 9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg (Figure 6a ), but not significantly as compared with the Ab 25-35 /Veh-treated group. The drug [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or Ab 25-35 peptide (9 nmol i.c.v.) at day 0. At day 7, they were tested for spontaneous alternation, at days 8 and 9, for passive avoidance response and killed. Their hippocampus was used for lipid peroxydation measure. Another batch of animals was used at days 6-8 for the novel object recognition test in (e, f). Data show the preferential exploration index calculated as the ratio of number of contact with the object in position #2 over the total number of contacts with the two objects, expressed as percentage. The number of mice per group was n ¼ 6 in (a), n ¼ 10 in (b-d), n ¼ 11-12 in (e, f). O po0.05, OO po0.01 vs 50% level, one-sample t-test in (f).
Blockade of Tau hyperphosphorylation and Ab 1-42 by ANAVEX2-73
V Lahmy et al blocked the Ab 25-35 -induced increase in P(Tyr 216 )GSK-3b, with a significant effect at the three highest doses tested (Figure 6b ). PRE-084 failed to affect the decrease in P(Ser 9 )GSK-3b significantly (Figure 6c ), but significantly blocked the increase in P(Tyr 216 )GSK-3b at the 1 mg/kg dose (Figure 6d ). The xanomeline treatment led to a significant blockade of the decrease in P(Ser 9 )GSK-3b induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Figure 6e) , at the dose of 1 mg/kg, and to a blockade of P(Tyr 216 )GSK-3b but with a significant effect measured for the lowest, 0.5 mg/kg, dose (Figure 6f) .
Consequently, the drug treatments impacted the Ab 25-35 -induced increases in Tau phosphorylation (Figure 7 (Figure 7e and f), but with significant effects in each case. It therefore appeared that all the drug treatments, ie, using the nonselective s 1 /muscarinic drug ANAVEX2-73, the s 1 selective agonist PRE-084 or the selective muscarinic ligand xanomeline, could efficiently block the pathological Tau hyper-phosphorylation and related kinase pathways induced by Ab 25-35 in mice.
Effect of Drug Treatments on Ab 1-42 Seeding in Ab 25-35 -treated Mice
As we previously reported (Meunier et al, 2013) , a significant 35-42% increase in endogenous Ab 1-42 content could be measured 7 days after Ab 25-35 injection in the mouse hippocampus, as compared with Sc.Ab-treated animals (Figure 8a-c) . The peptide injection failed, however, to affect endogenous Ab 1-40 content (Figure 8b) .
The ANAVEX2-73 treatment dose-dependently prevented the Ab 25-35 -induced increase in Ab 1-42 content, with a significant effect at the highest dose tested (Figure 8a) . Interestingly, the drug did not lower the Ab 1-42 level below baseline. Both PRE-084 and xanomeline also significantly attenuated the Ab 25-35 -induced increase in Ab 1-42 content with a significant effect at their lower dose tested (Figure 8c and d) . The induction of amyloidogenic pathway was also analyzed using western blot by measuring the C99 fragment produced by b-secretase cleavage of APP. Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced a significant 40-49% increase in C99 expression (Figure 9a-c) . The ANAVEX2-73 treatment dose-dependently prevented the Ab 25-35 -induced increase in C99 level, with highly significant effects at 0.3 and 1 mg/kg (Figure 9a ). PRE-084 failed to affect C99 expression (Figure 8b ), but xanomeline significantly prevented the Ab 25-35 -induced increase in C99 expression at the highest dose tested (Figure 9c ). These observations concomitantly suggested that ANAVEX2-73 is able to alleviate endogenous Ab 1-42 seeding induced by Ab 25-35 in mice, both by its muscarinic and s 1 properties.
DISCUSSION
The main finding in this study is that new therapeutic pathways can be found to alleviate the Tau pathology and amyloid seeding in AD using unconventional targets. We used, here, a mouse model where Ab 25-35 i.c.v. injection in mice results in kinase activation and Tau phosphorylation, on one hand, and increased levels of Ab 1-42 in the mouse hippocampus, on the other hand. Based on this model, we confirmed the central role of GSK-3b in the toxicity as drugs acting directly, as GSK-3b inhibitor, or indirectly, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or Sc.Ab (9 nmol) i.c.v. injection, at day 0. At day 6-8, they were used for the novel object recognition test. Data showed the preferential exploration index calculated as the ratio of number of contact with the object in position #2 over the total number of contacts with the two objects, expressed as percentage. (for GSK-3a) inhibits activity, whereas phosphorylation of Tyr 216 (for GSK-3b) or Tyr 279 (for GSK-3a) increases )GSK-3b/total GSK-3b ratio and (d-f) P (Tyr   216   ) GSK-3b/total GSK-3b ratio. Mice were administered with ANAVEX2-73 (0.1-1 mg/kg i.p.), PRE-084 (0.5, 1 mg/kg i.p.), xanomeline (0.5, 1 mg/kg i.p.), or saline (V) 20 min before the Ab 25-35 or Sc.Ab (9 nmol) i.c.v. injection, 7 days before killing. n ¼ 7-12, F (4,45) ¼ 2.81, po0.05 in (a); n ¼ 5-15, F (3,41) ¼ 2.91, po0.05 in (b); n ¼ 5-12, F (3,32) ¼ 5.09, po0.01 in (c); n ¼ 7-9, F (4,41) ¼ 2.62, po0.05 in (d); n ¼ 5-14, F (3,36) ¼ 4.28, po0.05 in (e); n ¼ 5-9, F (3,27) ¼ 9.51, po0.001 in (f). *po0.05, ** po0.01, ***po0.001 vs the (Sc.Ab þ V)-treated group; . GSK-3b is the main isoform involved in AD pathology. It must be outlined that inhibition of GSK-3b has more influence on activity than activation, as the enzyme is constitutively active and activation sites are )Tau/total Tau ratio. Mice were administered with ANAVEX2-73 (0.1-1 mg/kg i.p.), PRE-084 (0.5, 1 mg/kg i.p.), xanomeline (0.5, 1 mg/kg i.p.), or saline 20 min before the Ab 25-35 or Sc.Ab (9 nmol) i.c.v. injection, 7 days before killing. n ¼ 7-14, F (4,45) ¼ 4.58, po0.01 in (a); n ¼ 12-17, F (4,75) ¼ 3.59, p ¼ 0.01 in (b); n ¼ 5-7, F (3,22) ¼ 10.5, po0.001 in (c); n ¼ 5-11, F (3,35) ¼ 4.14, po0.05 in (d); n ¼ 5-7, F (3,24) ¼ 3.88, po0.05 in (e); n ¼ 4-14, F (3,36) ¼ 3.98, po0.05 in (f). *po0.05, **po0.01, ***po0.001 vs the (Sc.Ab þ V)-treated group; # po0.05, ## po0.01 vs the (Ab 25-35 þ V)-treated group; Dunnett's test.
Blockade of Tau hyperphosphorylation and Ab 1-42 by ANAVEX2-73 V Lahmy et al subjected to autophosphorylation (Cole et al, 2004) . One of the most characterized regulation pathways for GSK-3b is through protein kinase B (Akt) activation. Several receptors for neurotransmitters and neurotrophic factors, coupled to PI3K that phosphorylates Akt, in turn inhibit GSK-3b through phosphorylation of Ser 9 residue (Liu et al, 2003) . Other kinases such as PKC can also inhibit GSK-3b activity by phosphorylating Ser 9 (Liu et al, 2003) and this inhibition by PKC is additive to the inhibition by Akt.
Amyloid peptides, and particularly Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , have been reported to regulate Akt and GSK-3b activities, either in vitro (Yin et al, 2005) or in vivo. For instance, 12 days after Ab 25-35 , the levels of P(Ser 473 )-Akt/Akt ratio were decreased in ICR mice, an effect blocked by the s 1 receptor agonist ; Li et al, 2010) . This effect was accompanied by a decrease in mTOR phosphorylation, clearly involving a diminution of the PI3K/Akt/mTOR pathway in Ab 25-35 -induced toxicity. In turn, Ab provokes the hyperphosphorylation of Tau. Alternative mechanisms may, however, also be involved, including oxidative stress (Mattson et al, 1997) , perturbed cellular Ca 2 þ homeostasis (Mattson, 2004) , activation of other kinases, or inhibition of phosphatases (Stoothoff and Johnson, 2005) . In the present study, we confirmed that the i.c.v. injection of Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] resulted in a rapid, highly significant reduction of the P(Ser 473 )-Akt/Akt ratio, within 1 to 2 days after injection. Interestingly, we also observed a significant, but very transient, decrease in total Akt level, one day after the peptide injection (data not detailled). Other authors have reported, using combined microarray and RT-PCR analyses of gene expression profiles that Akt is downregulated in the cortex of Balb/c mice 14 days after i.c.v. Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection, at a dose that impeded water-maze learning (Kong et al, 2005) . Our results, however, suggested that the downregulation of Akt activity is an earlier event, appearing within days after the peptide injection and participating in the subsequent disorder of signalling pathways.
Indeed, GSK-3b activity appeared altered by Ab 25-35 . Klementiev et al (2007) first reported that in rat cingulate cortex, not only total GSK-3b and P(Tyr 216 )-GSK-3b, but also P(Ser 9 )-GSK-3b were increased after Ab 25-35 injection. We could observe an increase in P(Tyr 216 )-GSK-3b/GSK-3b ratio, but not in P( Ser 9 )-GSK-3b/GSK-3b ratio. By contrast, the latter diminished gradually with time after Ab 25-35 injection. These effects both signed an increase in GSK-3b activity that appeared long-lasting over the 7 days of measure. The time course was therefore different to what could be expected from the previous observation on Akt activity, suggesting that Akt is not the only kinase involved in the amyloid peptide effect on GSK-3b. Ab could therefore accelerate Tau phosphorylation by several mechanisms, notably GSK-3b activation (Takashima et al, 1993 (Takashima et al, , 1996 (Takashima et al, , 1998 . It has indeed been shown that Ab 25-35 treatment activated Tau, GSK-3b, but not GSK-3a or mitogenactivated protein kinase (MAP kinase), in primary culture of rat hippocampal neurons. In addition, treatment of the cultures with a GSK-3b-targeting antisense oligonucleotide inhibited the enhancement of Tau phosphorylation induced by Ab 25-35 exposure (Takashima et al, 1998) . Such observation clearly confirmed the specificity of the role of GSK-3b in amyloid toxicity and in linking amyloid toxicity and Tau hyperphosphorylation.
A GSK-3b Inhibitor Alleviates Ab 25-35 -induced Toxicity and Memory Deficits
The confirmation of the importance of GSK-3b activation in the amyloid toxicity must come from the demonstration of a therapeutic effect for agents (oligonucleotides or small molecules) that inhibit GSK-3b activity in vivo. We used Tibpo, an oxadiazole derivative inhibiting GSK-3b activity with an IC 50 of 390 nM (Naerum et al, 2002) . It was previously reported to increase the viability of cells transfected with G93A-or A4V-mutant types of human Cu/Zn-superoxyde dismutase gene, both lines being models of familial amyotrophic lateral sclerosis. This pro-survival effect relied on the activation of heat shock transcription factor-1 and reduction in cytochrome c release, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage (Koh et al, 2005) . In our model, the compound blocked the Ab 25-35 -induced phosphorylation of GSK-3b on Tyr 216 , and the induction of Tau phosphorylation, examined on Ser 202 ,Thr 205 or Ser 212 ,Thr 214 epitopes, using AT8 or AT100 anti-phospho-Tau antibody, respectively. It dose-dependently prevented the Ab 25-35 -induced oxidative stress in the hippocampus and memory alterations, in terms of spontaneous alternation, passive avoidance or object recognition, so affecting spatial and non-spatial, short-and long-term memories. We clearly measured the importance of GSK-3b activation in Ab toxicity and the pharmacological potential of such GSK-3b inhibitors. Indeed, an orally administrable-related oxidiazole, 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole (MMBO), was recently shown to decrease hippocampal Tau phosphorylation at GSK-3 sites, but without affecting Ab pathology, in the 3xTg transgenic AD mouse model. In behavioral assessments, MMBO significantly improved memory deficits in the Y-maze and novel object recognition tests (Onishi et al, 2011) . Therefore, these molecules appeared effective in preclinical tests. Their use in clinical trials may, however, be impeded by adverse effects due to the numerous cellular roles of GSK-3b.
The Mixed Muscarinic/r1 Ligand ANAVEX2-73 Prevent Tau Hyperphosphorylation in Ab 25-35 -injected Mice
The main purpose of the present study was to analyze ANAVEX2-73 effects on Tau pathology and Ab accumulation, by comparison with the reference and selective s 1 receptor agonist PRE-084 (Su et al, 1991) and the muscarinic ligand xanomeline, devoid of s 1 activity. Xanomeline has high affinity for M1 receptors (IC 50 ¼ 7 nM) as measured by the inhibition of [ 3 H]-pirenzepine binding in hippocampal and cortical membranes (Shannon et al, 1994) . It also has high affinity for inhibiting the binding of (Shannon et al, 1994) , a pharmacological profile comparable to ANAVEX2-73 but at higher affinities. The drug was already proven to be effective in patients with probable AD (Bodick et al, 1997) . We first confirmed that the three drugs attenuated the Ab 25-35 -induced behavioral impairments at low mg/kg doses, by using the novel object recognition procedure. Recognition memory is indeed rapidly and drastically degraded in AD patients. The efficacy of these drugs in the procedure was not previously reported. It confirmed the active dose range observed using the spontaneous alternation and passive avoidance procedures for PRE-084 (Meunier et al, 2006) or ANAVEX2-73 (Villard et al, 2011) . It also showed that xanomeline is active in the model in the dose range. We then reported that the decreases in P(Ser 473 )-Akt/Akt ratios, measured significantly at day 1 and 7 after Ab 25-35 , could be blocked by the three drugs at their behaviorally active doses. The resulting decrease in GSK-3b phosphorylation on Ser 9 was significantly blocked only by xanomeline but attenuated by ANAVEX2-73 and PRE-084. The three drugs, however, (Caccamo et al, 2006) . The M1 selective ligand (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one (AF267B) reduced the Tau pathology in the hippocampus and cortex of the mice, the HT7 and AT8 immunoreactivities in the same brain structures, and GSK-3b activity (Caccamo et al, 2006) . This last effect was directly attributable to an increase in PKC activity induced by AF267B. Indeed, Ab 25-35 not only decreases Akt activity but also PKC activity in the hippocampus and cortex (Olariu et al, 2001) . The efficacy of xanomeline in our model is therefore not surprising. It was clearly proposed that muscarinic ligands, through their ability to directly activate the PLC/PKC pathway, could very efficiently decrease the hyper-activation of GSK-3b in AD (Fisher, 2008 (Fisher, , 2012 .
The efficacy of a selective s 1 receptor ligand, like PRE-084, could also involve a facilitation of the PLC/PKC pathway. It was indeed shown that antidepressants (imipramine) enhance the brain-derived neurotrophic factor signalling on the PLC-g/IP 3 /Ca 2 þ pathway via activation of the s 1 receptor in primary rat neuron cultures (Yagasaki et al, 2006) . Moreover, Nakano et al (2010) directly demonstrated that the antidepressant (fluvoxamine) effect relied on a rapid increase in phosphorylation of Akt, as mimicked by brain-derived neurotrophic factor itself or by the s 1 receptor agonist DHEA sulfate. Our results, and the recent demonstration that both DHEA and pregnenolone sulfate prevented Ab 25-35 toxicity through a modulation of the PI3K/Akt/mTOR signalling Yang et al, 2012) , confirmed the in vivo efficacy of s 1 ligand to modulate GSK-3b activity. A direct interaction has not been shown yet, but it may involve either modulation of PKC activity or regulation of Ca 2 þ mobilization from the ER. As calcineurin, a major calcium-dependent protein phosphatase, has been shown to be able to dephosphorylate GSK-3b at Ser 9 (Kim et al, 2009) , local changes in Ca 2 þ , as the ones gated by the s 1 protein (Hayashi et al, 2000) , could modulate the kinase activity.
The Mixed Muscarinic/r1 Ligand ANAVEX2-73 Prevent Ab 1-42 Seeding in Ab 25-35 -injected Mice
We finally examined whether the drug treatments could also prevent the endogenous accumulation in Ab. It has been repeatedly shown that the i.c.v. injection of Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in rats and mice increases b-secretase activity and Ab levels in the hippocampus and cortex of the animals (Klementiev et al, 2007; Chavant et al, 2010; Zussy et al, 2011) . All treatments resulted in a significant blockade of Ab 25-35 -induced increase in Ab 1-42 levels measured by ELISA. When we analyzed the increase in C99 levels, PRE-084 appeared, however, less effective. Globally, the data suggested that the muscarinic activity of the compound is mainly involved in their ability to reduce the amyloid load in Ab 25-35 -treated animals. The mechanism involved in this effect may also rely on the PLC/PKC pathway activated by M1 muscarinic receptors, which has been shown to increase the activity of a-secretase, therefore preventing the formation of Ab (Nitsch et al, 1992) . The a-secretase involved is ADAM17, activated by PKCa/e isoforms (Cisse et al, 2011; Fisher, 2012) . Moreover, the AF267B treatment in 3xTg-AD transgenic mice, as detailled earlier, induced not only increases in PKC or MAP kinase, but also in ADAM17, accompanied by decreases in Ab, C99 GSK-3b, and BACE-1 levels (Caccamo et al, 2006) . Alternatively, whether s 1 protein activation could modulate secretase activities has not been directly addressed. But it is likely that s 1 ligand could impact Ab generation by different pathways, including the modulation of PI3K/Akt/PLC signalling as previously outlined. Moreover, secretase activity could be directly modulated by s 1 protein activation. First, isoflurane has been shown to activate BACE-1 via activation of the inositol 1,4,5-trisphosphate receptor, the main target of the s 1 protein, and the resulting Ca 2 þ deregulation may be a contributing factor in the mechanism of isoflurane-induced neurodegeneration (Zhao et al, 2010) . A similar mechanism could be evoked in AD. Second, oxidative stress, known to directly activate the s 1 protein (Meunier and Hayashi, 2010) , is associated with Ab accumulation in the brains of AD patients. Significant amounts of BACE-1 and g-secretase components localize in the cholesterol-rich region of membranes known as lipid rafts, where Ab production occurs preferentially and where s 1 protein accumulate after overactivation Su, 2001, 2003) . Oda et al (2010) observed that an oxidative stress enhanced presenilin-1 protein levels, a component of the g-secretase complex, in lipid rafts via upregulation of its transcription. This effect may constitute the mechanism underlying the oxidative stress-associated promotion of Ab production (Oda et al, 2010) , a mechanism likely to constitute the direct target of s 1 ligands.
Finally, our present data confirmed the pharmacological potentiality of mixed compounds, like ANAVEX2-73. The compound, although presenting a micromolar order of affinity for its pharmacological targets, showed a similar active dose as compared with the two selective compounds, both presenting nanomolar affinities for the muscarinic or s 1 receptor, allowing to limit the adverse effects usually observed with pure muscarinic receptor ligands. The present data clearly suggested that both receptors target GSK-3b activity and that inhibiting this kinase efficiently decreased Tau hyperphosphorylation and Ab accumulation in the AD model. These treatments are currently tested in AD transgenic mice, where the ability of the drugs to protect brain neurons degenerating in AD, together with an expected limitation of the Tau pathology and Ab seeding, could ultimately lead to a consequent disease-modifying activity. DISCLOSURE JM, SM, and VV are employees of Amylgen. AV is an employee of Anavex Life Sciences.
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